CDMOs offering Lentiviral Vector Manufacturing with Cell Therapy
16 published
16 published CDMOs match Lentiviral Vector Manufacturing and Cell Therapy.
Locations in this set include United States, China, United Kingdom, Japan, Belgium, and Denmark.
Capabilities that show up most often in this set: AAV Manufacturing, CMC Analytical Development, Cell-Line Development, Cell Therapy Manufacturing, and Viral Vector Manufacturing.
Matching companies
AGC BiologicsGlobal CDMO offering development and manufacturing for protein expression biologics, pDNA, mRNA, viral vectors (AAV, LVV, RVV), and genetically engineered cells with scale-out manufacturing capabilities.
AldevronAldevron is a CDMO specializing in mRNA manufacturing with LNP encapsulation and fill/finish, viral vector production, plasmid DNA, and gene therapy solutions from discovery through commercialization.
Andelyn BiosciencesCDMO specializing in plasmid DNA and AAV viral vector manufacturing for cell and gene therapy, with digital-first platform emphasizing data integrity and collaboration.
AsimovAsimov provides cell line development, upstream process development, and viral vector manufacturing services powered by proprietary synthetic biology platforms (CHO Edge, LV Edge, AAV Edge, RNA Edge) that deliver high-titer, stable cell lines and production systems for biologics, cell therapies, and gene therapies.
BioInnovatiseBioInnovatise provides fast, reliable CDMO services for plasmid DNA, viral vector packaging, and CRISPR-Cas9 research with turnaround times of 7–28 days.
CatalentGlobal CDMO providing end-to-end contract development and manufacturing for pharma, biotech, and consumer health. Delivers 60+ billion doses annually across small molecules, biologics, cell & gene therapies, and clinical supply.
Cell and Gene Therapy CatapultUK-based innovation and manufacturing support organization for cell and gene therapies, offering infrastructure, expertise, and collaboration across the ATMP lifecycle.
Charles River LaboratoriesCharles River Laboratories provides contract research, development, and manufacturing services across the full drug discovery and development continuum, supporting 80% of FDA-approved drugs over the past five years.
GenezenViral vector CDMO specializing in AAV, lentiviral, and retroviral manufacturing for gene and cell therapies, with cGMP facilities in Indiana and Massachusetts supporting preclinical through commercial-scale production.- HillgeneHillgene is a leading CDMO provider specializing in cell therapy manufacturing, offering end-to-end solutions for CAR-T, TCR-T, CAR-NK, and UCAR-T cell therapies with GMP facilities in Suzhou and Belgium.
Minaris Advanced TherapiesPure-play cell and gene therapy CDMO with over 25 years of GMP manufacturing, process development, and biosafety testing expertise. Serves advanced therapy innovators globally from early stage through commercialization.
OmniabioOmniaBio is a cell and gene therapy CDMO specializing in process development, analytical development, and GMP manufacturing for lentiviral vectors, iPSCs, and immune cell-based therapies. The company operates a 120,000 sq ft facility in Hamilton, Ontario, integrating AI, automation, and robotics to deliver scalable manufacturing from preclinical to commercial stages.
Oxford BiomedicaGlobal viral vector CDMO with 30 years of expertise in lentivirus, AAV, and adenovirus manufacturing. Provides end-to-end development and GMP-compliant manufacturing services from preclinical through commercial launch for cell and gene therapy programs.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Porton AdvancedEnd-to-end ATMP CDMO provider offering cell engineering, lentiviral vectors, mRNA/LNP, plasmid development, and GMP manufacturing from preclinical through commercialization with 24 IND approvals across NMPA, FDA, and MedSafe.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
Markdown mirror: /explore/lentivirus-manufacturing/cell-therapy.md